Acute heart failure or acute exacerbation of chronic heart failure within the past 2 weeks.
Scheduled cardiac resynchronization therapy or heart transplantation.
History of malignant tumor or life expectancy under 12 months.
Already on medications that may affect thyroid function (L-T4, carbimazole, propylthiouracil, amiodarone, lithium).
Pregnancy and lactation period.
Participation in another clinical trial within the past 30 days.
Contraindication or intolerance to evidence-based therapy for CHF, such as beta-blocker, angiotensin-converting enzyme inhibitor or angiotensin receptor blocker.
Known hypersensitivity to the trial treatment(s) or diluents (when applicable), including placebo or other comparator drug(s).
Untreated adrenal insufficiency.
Untreated pituitary insufficiency.
Untreated thyrotoxicosis.
Treatment with levothyroxine must not be initiated in patients with acute myocardial infarction, acute myocarditis, or acute pancarditis.
Severe renal dysfunction (eGFR=30 ml/min/1.73m2).
Significant hepatic impairment (Serum GPT > 120 U/L).
Any disorder which, in the opinion of the investigator, might jeopardise subject's safety or compliance with the protocol.

NCT03096613_exc_T1
Condition
Acute heart failure
NCT03096613_exc_T2
Condition
exacerbation
NCT03096613_exc_T3
Qualifier
acute
NCT03096613_exc_T4
Condition
chronic heart failure
NCT03096613_exc_T5
Temporal
within the past 2 weeks
NCT03096613_exc_T6
Scope
Acute heart failure or acute exacerbation of chronic heart failure
NCT03096613_exc_T7
Procedure
cardiac resynchronization therapy
NCT03096613_exc_T8
Procedure
heart transplantation
NCT03096613_exc_T9
Condition
malignant tumor
NCT03096613_exc_T10
Person
life expectancy
NCT03096613_exc_T11
Value
under 12 months
NCT03096613_exc_T12
Drug
medications
NCT03096613_exc_T13
Measurement
thyroid function
NCT03096613_exc_T14
Value
affect
NCT03096613_exc_T15
Drug
L-T4
NCT03096613_exc_T16
Drug
carbimazole
NCT03096613_exc_T17
Drug
propylthiouracil
NCT03096613_exc_T18
Drug
amiodarone
NCT03096613_exc_T19
Drug
lithium
NCT03096613_exc_T20
Scope
L-T4, carbimazole, propylthiouracil, amiodarone, lithium
NCT03096613_exc_T21
Condition
Pregnancy
NCT03096613_exc_T22
Condition
lactation period
NCT03096613_exc_T24
Condition
Contraindication
NCT03096613_exc_T25
Condition
intolerance
NCT03096613_exc_T26
Procedure
evidence-based therapy
NCT03096613_exc_T27
Condition
CHF
NCT03096613_exc_T28
Drug
beta-blocker
NCT03096613_exc_T29
Drug
angiotensin-converting enzyme inhibitor
NCT03096613_exc_T30
Drug
angiotensin receptor blocker
NCT03096613_exc_T31
Scope
beta-blocker, angiotensin-converting enzyme inhibitor or angiotensin receptor blocker
NCT03096613_exc_T32
Scope
Contraindication or intolerance
NCT03096613_exc_T33
Scope
Contraindication or intolerance to evidence-based therapy for CHF
NCT03096613_exc_T34
Procedure
trial treatment(s)
NCT03096613_exc_T35
Drug
reatm s (when
NCT03096613_exc_T36
Scope
trial treatment(s) or diluents
NCT03096613_exc_T37
Condition
hypersensitivity
NCT03096613_exc_T38
Drug
placebo
NCT03096613_exc_T39
Qualifier
other
NCT03096613_exc_T40
Drug
comparator drug(s)
NCT03096613_exc_T41
Scope
placebo or other comparator drug(s)
NCT03096613_exc_T42
Scope
hypersensitivity to the trial treatment(s) or diluents
NCT03096613_exc_T43
Condition
adrenal insufficiency
NCT03096613_exc_T44
Qualifier
Untreated
NCT03096613_exc_T45
Condition
pituitary insufficiency
NCT03096613_exc_T46
Qualifier
Untreated
NCT03096613_exc_T47
Condition
thyrotoxicosis
NCT03096613_exc_T48
Qualifier
Untreated
NCT03096613_exc_T49
Drug
levothyroxine
NCT03096613_exc_T50
Condition
acute myocardial infarction
NCT03096613_exc_T51
Negation
not be initiated
NCT03096613_exc_T52
Procedure
Treatment
NCT03096613_exc_T53
Condition
acute myocarditis
NCT03096613_exc_T54
Condition
acute pancarditis
NCT03096613_exc_T55
Scope
acute myocardial infarction, acute myocarditis, or acute pancarditis
NCT03096613_exc_T56
Condition
renal dysfunction
NCT03096613_exc_T57
Qualifier
Severe
NCT03096613_exc_T58
Measurement
eGFR
NCT03096613_exc_T59
Value
=30 ml/min/1.73m2
NCT03096613_exc_T60
Scope
eGFR=30 ml/min/1.73m2
NCT03096613_exc_T61
Scope
Severe renal dysfunction
NCT03096613_exc_T62
Condition
hepatic impairment
NCT03096613_exc_T63
Qualifier
Significant
NCT03096613_exc_T64
Measurement
Serum GPT
NCT03096613_exc_T65
Value
> 120 U/L